Why the study?
Does ticagrelor reduce ischaemic events compared to clopidogrel in patients with acute coronary syndromes and diabetes?
Does ticagrelor reduce ischaemic events compared to clopidogrel in patients with acute coronary syndromes and diabetes?
Ticagrelor is superior to clopidogrel in reducing ischemic events in ACS patients regardless of their diabetes status or glycemic control, without increasing major bleeding risk.
Answers are grounded in this paper and cite their sources.
Supports ticagrelor over clopidogrel in ACS irrespective of diabetes; extends PLATO consistency across glycaemic control without excess bleeding.
ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.
No takes yet. Share an insight, caveat, or question.
James et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: